000020792 001__ 20792
000020792 005__ 20201126102421.0
000020792 0247_ $$2ISSN$$a1866-1785
000020792 0247_ $$2Handle$$a2128/4558
000020792 020__ $$a978-3-89336-782-5
000020792 037__ $$aPreJuSER-20792
000020792 041__ $$aGerman
000020792 082__ $$a500
000020792 082__ $$a610
000020792 1001_ $$0P:(DE-Juel1)VDB84576$$aOkrob, Danial$$b0$$eCorresponding author$$gmale$$uFZJ
000020792 245__ $$aOptimierung der Hydroxynitril-Lyase aus Arabidopsis thaliana für die enantio-selektive Synthese von (R)-Cyanhydrinen: Entwicklung und Etablierung geeigneter Reaktionsparameter und molekulare Stabilisierung durch rationales Enzymdesign
000020792 260__ $$aJülich$$bForschungszentrum Jülich GmbH Zenralbibliothek, Verlag$$c2012
000020792 300__ $$aXV, 135 S.
000020792 3367_ $$0PUB:(DE-HGF)11$$2PUB:(DE-HGF)$$aDissertation / PhD Thesis
000020792 3367_ $$0PUB:(DE-HGF)3$$2PUB:(DE-HGF)$$aBook
000020792 3367_ $$02$$2EndNote$$aThesis
000020792 3367_ $$2DRIVER$$adoctoralThesis
000020792 3367_ $$2BibTeX$$aPHDTHESIS
000020792 3367_ $$2DataCite$$aOutput Types/Dissertation
000020792 3367_ $$2ORCID$$aDISSERTATION
000020792 4900_ $$0PERI:(DE-600)2422127-2$$aSchriften des Forschungszentrums Jülich. Reihe Gesundheit / Health$$v53
000020792 502__ $$aUniversität Düsseldorf, Diss., 2012$$bDr. (Univ.)$$cUniversität Düsseldorf$$d2012
000020792 500__ $$3POF3_Assignment on 2016-02-29
000020792 500__ $$aRecord converted from JUWEL: 18.07.2013
000020792 500__ $$aRecord converted from VDB: 12.11.2012
000020792 520__ $$aIn this work the potential of the hydroxynitrile lyase from $\textit{Arabidopsis thaliana}$ (AtHNL) for the enantioselective synthesis of industrially important cyanohydrins was demonstrated by two different principles: reaction- and protein engineering. The enantiomeric excess of this enzymatic reaction is strongly compromised by a non-selective side-reaction resulting in racemic cyanohydrins and thus lowering the enantiomeric excess of the biotransformation. This non-selective product formation is influenced by pH, temperature and the water content of the reaction medium. For industrial applications aqueous or aqueous-organic reaction systems are used where the racemic product formation is suppressed by lowering the pH below pH 5 and running the process at $\le$ 10 °C. However, both approaches are not feasible with AtHNL, since the enzyme is rapidly inactivated below pH 5. In order to enable the use of AtHNL for the enantioselective synthesis of industrial important cyanohydrins two strategies were developed in this work. The first strategy concerned the suppression of the racemic product formation by reaction engineering. Thereby, a micro-aqueous reaction medium (buffer-saturated mono-phasic methyl $\textit{tert}$. butyl ether) was used to suppress the undesired side reaction, which resulted in a good enzymatic activity and high enantioselectivities for several industrially important cyanohydrins. Efficient cyanohydrin syntheses were reached in the established reaction system by application of whole cells and the use of immobilized enzyme (e.g., enzyme adsorption at celite particles, encapsulation in solgel, cross-linking of enzyme aggregates), espectively. Best results were obtained using whole recombinant $\textit{E. coli}$ cells as well as celite-adsorbed isolated AtHNL. For the synthesis of (R)- mandelonitrile both preparations showed comparable catalytic efficiencies, process-and storage stabilities, resulting in a maximal productivity of ~1.6 g (R)-mandelonitrile per g wet cell mass (after 6-8 recycling steps). The second strategy was the development of a stabilized AtHNL variant which is stable under acidic conditions and thus applicable in industrially established aqueous-organic two-phase reaction systems. Based on the highly similar HNL from $\textit{Manihot esculenta}$ (MeHNL), which is stable under these conditions, the protein [...]
000020792 536__ $$0G:(DE-Juel1)FUEK410$$2G:(DE-HGF)$$aBiotechnologie$$cPBT$$x0
000020792 655_7 $$aHochschulschrift$$xDissertation (Univ.)
000020792 8564_ $$uhttps://juser.fz-juelich.de/record/20792/files/Gesundheit_53.pdf$$yOpenAccess
000020792 8564_ $$uhttps://juser.fz-juelich.de/record/20792/files/Gesundheit_53.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000020792 8564_ $$uhttps://juser.fz-juelich.de/record/20792/files/Gesundheit_53.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000020792 8564_ $$uhttps://juser.fz-juelich.de/record/20792/files/Gesundheit_53.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000020792 909CO $$ooai:juser.fz-juelich.de:20792$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000020792 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000020792 9141_ $$y2012
000020792 9131_ $$0G:(DE-Juel1)FUEK410$$1G:(DE-HGF)POF2-890$$2G:(DE-HGF)POF2-800$$baußerhalb PoF$$kPBT$$lohne FE$$vBiotechnologie$$x0
000020792 9132_ $$0G:(DE-HGF)POF3-589H$$1G:(DE-HGF)POF3-580$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lKey Technologies for the Bioeconomy$$vAddenda$$x0
000020792 920__ $$lyes
000020792 9201_ $$0I:(DE-Juel1)VDB56$$gIBT$$kIBT-2$$lBiotechnologie 2$$x0$$zab 31.10.10 weitergeführt IBG-1
000020792 970__ $$aVDB:(DE-Juel1)136501
000020792 980__ $$aVDB
000020792 980__ $$aConvertedRecord
000020792 980__ $$aphd
000020792 980__ $$aI:(DE-Juel1)IBG-1-20101118
000020792 980__ $$aUNRESTRICTED
000020792 980__ $$aJUWEL
000020792 980__ $$aFullTexts
000020792 9801_ $$aFullTexts
000020792 981__ $$aI:(DE-Juel1)IBG-1-20101118